Serum calcium, albumin and tumor stage in cutaneous malignant melanoma

Mridul Datta, Paul Savage, James Lovato, Gary G. Schwartz

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Aim: Assess the relationship of serum calcium and serum albumin to tumor stage and other clinical characteristics in patients with cutaneous malignant melanoma (MM). Patients & methods: A cross-sectional study to evaluate serum calcium as a marker of disease progression (n = 644) in MM. Results: Serum albumin was significantly lower among men (p < 0.01) and among patients with stage 4 disease (p < 0.05). In a multivariable regression model adjusted for age, gender and site, albumin-corrected calcium was positively associated with disease stage (odds ratio: 1.46; 95% CI: 1.02-2.07; p = 0.04). The odds of higher stage increased 60% for each 1.0 mg/dl increase in albumin-corrected calcium. Conclusion: Higher albumin-corrected serum calcium may be a marker of disease progression in MM.

Original languageEnglish (US)
Pages (from-to)2205-2214
Number of pages10
JournalFuture Oncology
Issue number19
StatePublished - Oct 2016
Externally publishedYes


  • Albumin
  • Albumin-corrected calcium
  • Malignant melanoma
  • Serum calcium

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Serum calcium, albumin and tumor stage in cutaneous malignant melanoma'. Together they form a unique fingerprint.

Cite this